Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia

BACKGROUND: The RECOVERY clinical trial reported that 6 mg of dexamethasone once daily for up to 10 days reduces the 28-day mortality in patients with coronavirus disease 2019 (COVID-19) receiving respiratory support. In our clinical setting, a fixed dose of dexamethasone has prompted the question o...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaka, Yuri, Hirasawa, Yasutaka, Terada, Jiro, Shionoya, Yu, Takeshita, Yuichiro, Kinouchi, Toru, Koshikawa, Ken, Tajima, Hiroshi, Kinoshita, Taku, Tada, Yuji, Tatsumi, Koichiro, Tsushima, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677429/
https://www.ncbi.nlm.nih.gov/pubmed/34923122
http://dx.doi.org/10.1016/j.pupt.2021.102108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677429/
https://www.ncbi.nlm.nih.gov/pubmed/34923122
http://dx.doi.org/10.1016/j.pupt.2021.102108

Ejemplares similares